ILEX Oncology Seeks to Become Premier Oncology Drug Development Company

Strategic Insights -

ILEX Oncology, a San Antonio-based firm, aims to establish itself as the leading developer of anticancer drugs, as stated by its President and CEO, Richard Love, at the BIO '98 Investor & Partnering Conference. The company has built a strong portfolio of seven anticancer drugs in clinical development, with two others in preclinical testing. ILEX is focusing on oncology as an exploding area of opportunity and interest, with a lead drug candidate, CAMPATH-1H, expected to file for marketing approval in 1999. The company is also utilizing its expertise to offer a full range of drug development services on a contract basis to pharmaceutical and biotechnology clients.

Key Takeaways:

  • ILEX Oncology is positioned to become the premier oncology drug development company, with a focus on accelerating the development of anticancer drugs through strategic alliances and staff expertise.
  • The company has a portfolio of seven anticancer drugs in clinical development, with two others in preclinical testing.
  • ILEX's lead drug candidate, CAMPATH-1H, is expected to file for marketing approval in 1999.
  • The company offers a full range of drug development services on a contract basis to clients in both the United States and Europe.
  • ILEX is using its expertise to acquire, develop, and commercialize a portfolio of important drug candidates.
  • The company's unique business model combines an advanced product portfolio with a strategically advantaged services business.
  • Cancer is a major societal problem, and ILEX is well-positioned to address these market opportunities due to its exclusive oncology focus, specialized expertise, and sound capital position.

Statistics:

  • ILEX Oncology has seven anticancer drugs in clinical development.
  • Two of the company's drugs are being developed to prevent cancer by stopping the occurrence, progression, or recurrence of pre-malignant conditions.
  • ILEX is offering a full range of drug development services to clients in both the United States and Europe.
  • The company's lead drug candidate, CAMPATH-1H, is expected to file for marketing approval in 1999.

Sources:

  • ILEX Oncology, Inc. (Nasdaq: ILXO)
  • http://www.ilexoncology.com
  • ILEX Oncology, Inc. (SEC filings)
  • BIO '98 Investor & Partnering Conference, 1998
  • Private Securities Litigation Reform Act of 1995